Skip to main content

rituximab (MabThera®)


Following a directed appraisal

AWMSG advice

Status: Recommended

Rituximab (MabThera®) is recommended as an option for use within NHS Wales for the treatment of patients with moderate to severe pemphigus vulgaris.

Rituximab should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance.

Existing health technology assessment (HTA) advice for the ‘reference’ medicine, published by AWMSG or the National Institute for Health and Care Excellence (NICE), will automatically apply for biosimilar medicines licensed for the same indication and in the same population as the ‘reference’ medicine.

Rituximab should be prescribed on the basis of lowest acquisition cost.

 Final Recommendation: rituximab (MabThera) 3192 (PDF, 339Kb)
 Appraisal Report: rituximab (MabThera) 3192 (PDF, 365Kb)

Medicine details

Medicine name rituximab (MabThera®)
Formulation 100mg concentrate for solution for infusion, 500mg concentrate for solution for infusion
Reference number 3192

For the treatment of patients with moderate to severe pemphigus vulgaris

Company Roche Products Ltd
BNF chapter Skin
Submission type Directed
Status Recommended
Advice number 1622
NMG meeting date 06/07/2022
AWMSG meeting date 14/09/2022
Date of issue 03/10/2022
Follow AWTTC: